Theratechnologies Inc T.TH

China deal

[scarlet1967]

“Tasly obtains exclusive development and commercialization rights for STRO-002 for Greater China -

- License includes a $40 million upfront payment to Sutro, and potentially up to $345 million in development and commercial milestone payments”

 

https://www.prnewswire.com/news-releases/sutro-biopharma-and-tasly-biopharmaceuticals-enter-into-exclusive-license-agreement-for-stro-002-in-greater-china-301450798.html

They will also discuss the interim data from their Phase 1 trial in January for their ADC.

 

https://finance.yahoo.com/news/sutro-biopharma-announces-company-kol-120000956.html

[Wino115]

This is one of our better "comps" as discussed by others here. Here's their announcement today about an interim dose trial release. Notice, they give over a weeks advanced notice of a data release, combine it with the investigator, remind investors what the FDA rules were, dates, patients, next steps. A good model for THTX too follow. Don't do that 8am surprise all in one release

[qwerty22]

It's also a good comp on the timetable for enrolment, 44 patients in 11 months ... but u r right a super bullish statement about their future. I'm sure it helps to have the China.

[qwerty22]

Such a nice deal for them to secure.

[scarlet1967]

Often we speculate when a deal should be done earlier with less upfront payment, loyalties etc or later on when there has been some results, This company although they are further in process with their trial than THTX decided based on most likely some encouraging results so far to close a deal relatively early only based on interim results from their phase1 trial. In case of THTX if and when their

[SPCEO1]

Somewhat like the other China partnership noted here recently, the stock of STRO is not really benefitting much. The upfront payment alone for STRO is worth nearly $1 per share but the stock is only up about half of that. Does the market not value Chinese partnership deals all that highly? STRO is an intersesting comparison to  THTX. They have about $60 million in revenues from some other

[Bucknelly21]

Almost back in the 2's what a joke

[PWIB123]

$2.95 - This is incredibly discouraging!  Probably some last minute sellers before year-end forcing the price down, but my goodness, this looks bad.

[scarlet1967]

Looking at their pipeline apart from some preclinical their most advanced program is their ADC in various cancers, it seems the interim results are for phase1a trial so early results yet they got that deal The issue with THTX is funds, they want to start the NASH with or without partners next year and raise funds on a shareholder friendly basis so investors who are following the company want to be

[jfm1330]

I looked at Sutro's corporate presentation. If you remove the cash position for both companies, you can see that the SP of Thera is not undervalued when you compare it to Sutro. They have a wider more advanced pipeline with good results in dose escalation phase I. But contrary to Thera's trial, it is all comers with ovarian cancer. So not selected for folate receptor alpha. They got 10

[scarlet1967]

It seems there was a delayed reaction as STRO is up almost 10 per cent today so far!

[qwerty22]

It had such a horrible 2021 in terms of SP. I'm thinking it might reclaim all those losses in 2022. It seems it deserves it but it another biotech that's just trying to execute and not promote. I'm tempted to get in before the KOL event???

[Wino115]

My understanding of the PRC market for pharmaceuticals is that you more or less have to partner with a local-based marketing/distribution firm and perhaps manufacturing too. Between the regulatory hassle, distribution complexity and a government trying to spur their domestic industry on, it's way too hard for pharma's to do on their own so they license out the PRC rights.  As for how

[scarlet1967]

I am not sure how the IP protection works but one can only assume all the recent collaborations with Chinese companies would not have been finalized if it was nothing in the contracts to protect the IP. I recall seeing some articles about Wuxi having a go at manufacturing ADCs I found it(below)also they seem to have plans setting up sites in the US. https://www.fiercepharma.com/manufacturing